§
Cui Bono
Bills Search Find My Rep Legislators Who Benefits Countries Methodology

S1373-118

Introduced

To increase access to medication for opioid overdose reversal, and for other purposes.

118th Congress Introduced Apr 27, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill requires GAO study on naloxone access. It relies on reporting requirements, compliance mandates, product standards, and exemptions. The main policy areas are Healthcare Consumers and Healthcare.

Who Benefits and How

Patients and health care consumers affected by the bill could face lower compliance burdens.

Who Bears the Burden and How

Federal, state, or local agencies responsible for implementing the clause would take on compliance duties and Public beneficiaries or protected communities affected by the clause could face increased risk.

Key Provisions

  • Requires GAO study on naloxone access.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill requires GAO study on naloxone access.

Key Policy Areas

Healthcare Consumers, Healthcare

Primary Purpose

The bill requires GAO study on naloxone access.

Policy Domains

Healthcare Consumers Healthcare

Whole bill

Identified Gains
  • Patients and health care consumers affected by the bill
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: is
Patients and health care consumers affected by the bill:
Identified Costs
  • Federal, state, or local agencies responsible for implementing the clause
  • Public beneficiaries or protected communities affected by the clause
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: is
Public beneficiaries or protected communities affected by the clause:
Federal, state, or local agencies responsible for implementing the clause:

Sponsors

Edward J. Markey

Edward J. Markey

D-MA | Primary Sponsor

3 cosponsors

Legislative Progress

Introduced
Introduced Committee Passed
Apr 27, 2023

Mr. Markey (for himself, Mr. Booker, Mr. Marshall, and Mr. …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Consumers Healthcare

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology